Pilot study of pharmacological treatment for frontotemporal dementia: Effect of Yokukansan on behavioral symptoms
Article first published online: 24 MAR 2010
© 2010 The Authors. Journal compilation © 2010 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 64, Issue 2, pages 207–210, April 2010
How to Cite
Kimura, T., Hayashida, H., Furukawa, H. and Takamatsu, J. (2010), Pilot study of pharmacological treatment for frontotemporal dementia: Effect of Yokukansan on behavioral symptoms. Psychiatry and Clinical Neurosciences, 64: 207–210. doi: 10.1111/j.1440-1819.2010.02072.x
- Issue published online: 24 MAR 2010
- Article first published online: 24 MAR 2010
- Received 16 November 2009; revised 26 December 2009; accepted 10 January 2010.
- antipsychotic agents;
- behavioral symptoms;
- frontotemporal dementia;
- neuropsychiatric inventory;
The aim of the present study was to investigate the efficacy of Yokukansan in improving behavioral symptoms of frontotemporal dementia. This study was a prospective, open-label trial of daily Yokukansan for 4 weeks in 20 frontotemporal dementia patients. Yokukansan treatment was found to significantly improve scores for the Neuropsychiatric Inventory and the Stereotypy Rating Inventory. No adverse effects or significant changes in physical findings and laboratory data occurred except for hypokalemia in two cases. The results indicate that Yokukansan can alleviate the behavioral symptoms of frontotemporal dementia. (The clinical trial registration number is UMIN000002704).